CTM vs NVDA

The deterministic health profile is severely compromised, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. While the company maintains a strong liquidity position (Current Ratio 4.40) and positive revenue growth (21.9%), these are offset by consistent net losses and a total lack of earnings beats. Bearish technical trends and aggressive insider selling further signal a lack of confidence in the short-to-medium term outlook.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.